The New England biotech hub has been on a roll the past couple years, with the breakout success of Vertex Pharmaceuticals, the ongoing revival at Biogen Idec, Sanofi’s $20 billion acquisition of Genzyme, and the continuing concentration of Big Pharma R&D in Boston. But both the science and business of biotech move fast. So which companies, and which entrepreneurs, are the ones to watch for the next five to 10 years? We’ll have keynotes from two of Boston’s biotech leaders. We’ll hear from the CEOs of five biotech startups that are gaining traction in the industry. And we’ll have an interactive panel discussion about an important but sometimes overlooked source of startup funding: grants from non-profit disease foundations. Join us for this extraordinary gathering of up-and-comers in the New England biotech hub.
Keynote Speakers
- George Scangos
- CEO, Biogen Idec
- Mark Levin
- Partner, Third Rock Ventures
Featured Speakers
- Chip Clark
- CEO, Genocea
- Doug Fambrough
- CEO, Dicerna
- Tillman Gerngross
- CEO, Adimab
- Joanna Horobin
- CEO, Syndax
- Joseph Yanchik
- CEO, Aileron
- Louise Perkins
- Chief Scientific Officer, Multiple Myeloma Foundation
- Julia Greenstein
- Assistant Vice President, Cure Therapies, Juvenile Diabetes Research Foundation
- Dana Callow
- Managing General Partner, Boston Millennia Partners; Board Member, Leukemia & Lymphoma Society
- Michael Kauffman
- CEO, Karyopharm
- Jens Eckstein
- President, SR One
- Doug Williams
- Executive Vice President, Research and Development, Biogen Idec
Schedule
Registration: 12:30 – 1:30 pm
Program: 1:30 – 5:30 pm
Networking Reception: 5:30 – 6:30 pm
Registration Information
Super Saver Rate (ends Feb. 8) $175
Regular Registration: $295
Startup Special: $175
For employees of startups less than 3 years old with 20 or fewer employees
Walk-in Registration: $350
Student Registration: $50
Student scholarships available through the Stay in MA program.
